Immunocore Expands IO Pact With Genentech To Target MAGE-A Antigens

Genentech and Immunocore will now co-develop the biotech's therapeutic candidate IMC-C103C, an ImmTAC molecule targeting tumors that express melanoma-associated antigen A4.